The USA-India Chamber of Commerce (USAIC) has announced the agenda of its 17th annual BioPharma & Healthcare Summit, which will be held virtually on May 3, 2023. The summit aims to support the BioPharma community in these unprecedented times.
US FDA Commissioner Dr Robert Califf will attend the event. Johnson & Johnson’s chairman and CEO, Joaquin Duato, Pfizer’s chairman and CEO Albert Bourla, Biogen’s CEO Christopher Viehbacher, Merck’s former chairman & CEO Kenneth Frazier, and academic leaders from Harvard and MIT have demonstrated interest to collaborate with India, the release stated.
According to the release, USAIC is a powerful platform for shared learning on science and technology and is crucial for successful performance in the complex world of BioPharma and Healthcare.
On fostering innovation, Karun Rishi, president of USAIC, said, "I am encouraged by the response of young colleagues. They are the future leaders in the healthcare and life science industry. We must do everything to help the next generation of leaders."
"I see India on the path to becoming an innovation powerhouse in BioPharma in the coming years. India has tremendous needs and potential in the area of BioPharma and Healthcare Innovation,” Rishi noted while adding they should scale up research and development, translational research, industry-academic partnerships, clinical trial or manufacturing.
The summit will have a special session to discuss BioPharma research and development, clinical trials, and the global supply chain by bringing together G20 Sherpa Amitabh Kant and industry leaders. “Today’s healthcare challenges are complex. A united global response will be more effective than individual countries acting independently. India’s leadership at G20 this year can be a defining moment to address these critical issues for patients worldwide,” Rishi added.
Andrew Plump, president of R&D, Takeda and Chair, of USAIC BioPharma & Healthcare Summit, excited to participate in the summit, said, "This year, with India on track to become the world’s most populous country, our responsibility to ensure its people benefit from these innovations that improve human health has never been greater."
Meanwhile, Amitabh Kant, India's G20 Sherpa, urged G20 member countries, businesses, academics, and scientists to collaborate and focus on evidence-based research and analytics to ensure preparedness in health systems and build adaptable global supply chains that can deliver instantaneously during a crisis.
